LeonaBio, Inc. (LONA)
NASDAQ: LONA · Real-Time Price · USD
10.99
+0.67 (6.49%)
May 14, 2026, 1:26 PM EDT - Market open
LeonaBio Employees
LeonaBio had 19 employees as of December 31, 2025. The number of employees decreased by 7 or -26.92% compared to the previous year.
Employees
19
Change (1Y)
-7
Growth (1Y)
-26.92%
Revenue / Employee
n/a
Profits / Employee
-$6,811,263
Market Cap
103.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 19 | -7 | -26.92% | 19 | 0 |
| Dec 31, 2024 | 26 | -41 | -61.19% | 26 | 0 |
| Dec 31, 2023 | 67 | 3 | 4.69% | 65 | 2 |
| Dec 31, 2022 | 64 | 29 | 82.86% | 63 | 1 |
| Dec 31, 2021 | 35 | 13 | 59.09% | 34 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| enGene Therapeutics | 82 |
| Vivani Medical | 42 |
| Cue Biopharma | 29 |
| Oncolytics Biotech | 29 |
| Q32 Bio | 24 |
| NeurAxis | 24 |
| ProMIS Neurosciences | 11 |
LONA News
- 6 days ago - LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 7 days ago - LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. - GlobeNewsWire
- 15 days ago - LeonaBio Transcript: Status update - Transcripts
- 20 days ago - LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer - GlobeNewsWire
- 23 days ago - LeonaBio presented data on lasofoxifene research at AACR26 - TheFly
- 24 days ago - Eight option delistings on April 20th - TheFly
- 5 weeks ago - LeonaBio price target raised to $16 from $10 at Mizuho - TheFly
- 6 weeks ago - LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire